Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Prilosec 1 Use For GERD Endorsed In 16-2 Joint Committee Vote

This article was originally published in The Tan Sheet

Executive Summary

Possible long-term use of omeprazole to prevent chronic heartburn or gastroesophageal reflux disease (GERD) is acceptable, despite an OTC indication for only 14-day use, FDA advisory committee members determined at a meeting in Bethesda, Md. June 21

Related Content

Prilosec OTC Bioequivalence To Rx Version “Has No Impact” – P&G
Prilosec OTC Leads Stomach Remedy Market; Consumer Use Data Published
Prilosec OTC Approved In 28-, 42-Count Multiple Regimen Sizes
OTC Prilosec Risk/Benefit Ratio Relative To Current OTCs Questioned By Andrx
Prilosec 1 “approvable”
Pepcid Marketing Strategy To Stay Unchanged In Face Of Prilosec 1 Launch
Prilosec 1 Self-Selected Correctly By 81% Of Actual Use Study Participants
Two GDAC Members Weigh In On Prilosec 1 Without Voting
Annual Use Limitations For Prilosec 1 Should Appear In Labeling – NDAC/GDAC
OTC Heartburn Drug Uniform Warnings Advocated By Advisory Panels





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts